pyrazolanthrone has been researched along with Leukemia, Myelomonocytic, Acute in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Breslin, P; Chen, J; Kuo, PC; Li, J; Li, X; Li, Z; Liu, X; Nand, S; Schmidt, R; Volk, A; Wei, W; Xiao, Y; Xin, J; You, D; Zhang, J; Zhang, Z | 1 |
1 other study(ies) available for pyrazolanthrone and Leukemia, Myelomonocytic, Acute
Article | Year |
---|---|
Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML.
Topics: Animals; Anthracenes; Blotting, Western; Cell Line, Tumor; Cell Survival; Cells, Cultured; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; JNK Mitogen-Activated Protein Kinases; K562 Cells; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Mice; Mice, Knockout; NF-kappa B; Nitriles; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sulfones; Transcription Factor AP-1; Tumor Necrosis Factor-alpha; U937 Cells | 2014 |